Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
BDX Stock News and Mentions of Becton Dickinson and Company Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Becton Dickinson Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Becton Dickinson and Company (BDX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Becton Dickinson stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Becton Dickinson and Company (BDX)
April 26, 2024 (17:19) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Receives FDA Warning Letter Regarding CT Systems
Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.
In Article Trend: Neutral
April 26, 2024 (11:29) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Q1 Earnings Beat, Strong CGM Demand Continues
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
In Article Trend: Somewhat-Bullish
April 25, 2024 (18:40) / "Benzinga" (by Zacks)
West Pharmaceutical Q1 Earnings Beat, HVP Sales Weak - Becton Dickinson ( NYSE:BDX ) , Ecolab ( NYSE:ECL )
West Pharmaceutical Services, Inc. WST reported first-quarter 2024 adjusted earnings per share EPS of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The bottom line, however, was down 21.2% year over year. The adjustments include expenses related to the amortization of ...
In Article Trend: Neutral
April 25, 2024 (16:50) / "Zacks Commentary" (by Zacks Equity Research)
Revvity's ( RVTY ) New Launch to Boost Tuberculosis Testing
Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
In Article Trend: Somewhat-Bullish
April 25, 2024 (16:44) / "Zacks Commentary" (by Zacks Equity Research)
CONMED ( CNMD ) Q1 Earnings & Revenues Surpass Estimates
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.
In Article Trend: Somewhat-Bullish
April 25, 2024 (16:37) / "Zacks Commentary" (by Zacks Equity Research)
Veeva's ( VEEV ) AI Partner Program to Develop GenAI Solutions
Veeva (VEEV) announces the Veeva AI Partner Program, which is expected to provide partners assistance to combine Generative AI solutions with Veeva Vault applications.
In Article Trend: Somewhat-Bullish
April 25, 2024 (14:31) / "Zacks Commentary" (by Zacks Equity Research)
West Pharmaceutical ( WST ) Q1 Earnings Beat, HVP Sales Weak
West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
In Article Trend: Neutral
April 24, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
Penumbra's ( PEN ) New Launch to Enhance Blood Clot Removal
Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
In Article Trend: Somewhat-Bullish
April 23, 2024 (17:42) / "Zacks Commentary" (by Zacks Equity Research)
Reasons Why You Should Retain HealthEquity ( HQY ) Stock for Now
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 23, 2024 (17:38) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) New Tie-Up to Boost Patient Outcomes
GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions.
In Article Trend: Neutral
April 22, 2024 (12:28) / "Zacks Commentary" (by Nalak Das)
Top 5 U.S. Giants at Lucrative Valuations Amid April Turmoil
We have narrowed our search to five U.S. bigwigs (market capital > $70 billion) with attractive valuations. These are: NVDA, MU, BDX, ANET, EQIX.
In Article Trend: Somewhat-Bullish
April 19, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
BDX or MMSI: Which Is the Better Value Stock Right Now?
BDX vs. MMSI: Which Stock Is the Better Value Option?
In Article Trend: Bullish
April 17, 2024 (14:30) / "Benzinga" (by Globe Newswire)
Blood Collection Market size worth $ 14.76 Billion, Globally, by 2031 at 5.10% CAGR - Report By Verified Market Research®
Jersey City, New Jersey, April 17, 2024 ( GLOBE NEWSWIRE ) -- The Global Blood Collection Market is projected to grow at a CAGR of 5.10% from 2024 to 2031, according to a new report published by Verified Market Research®.
In Article Trend: Somewhat-Bullish
April 16, 2024 (14:56) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad ( BIO ) Hurt by Softness in BioPharma and Competition
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
In Article Trend: Neutral
April 15, 2024 (14:15) / "Benzinga" (by Globe Newswire)
Wearable Injectors Market size worth $ 21.48 Billion, Globally, by 2031 at 15.30% CAGR - Report By Verified Market Research®
Jersey City, New Jersey, April 15, 2024 ( GLOBE NEWSWIRE ) -- The Global Wearable Injectors Market is projected to grow at a CAGR of 15.30% from 2024 to 2031, according to a new report published by Verified Market Research®.
In Article Trend: Somewhat-Bullish
April 12, 2024 (15:04) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold BD ( BDX ) Stock in Your Portfolio
BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 12, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Apheresis Market Worth $3.9 billion | MarketsandMarkets™
CHICAGO, April 12, 2024 /PRNewswire/ -- Apheresis Market in terms of revenue was estimated to be worth $2.6 billion in 2024 and is poised to reach $3.9 billion by 2029, growing at a CAGR of 8.8% from 2024 to 2029 according to a new report by MarketsandMarkets™.
In Article Trend: Somewhat-Bullish
April 9, 2024 (14:15) / "PR Newswire"
BD Named a Best Employer for Excellence in Employee Well-Being - PR Newswire
BD Named a Best Employer for Excellence in Employee Well-Being PR ...
In Article Trend: Bullish
April 8, 2024 (14:27) / "Zacks Commentary" (by Zacks Equity Research)
BD's ( BDX ) Latest Product to Offer Wider Access to Researchers
The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.
In Article Trend: Somewhat-Bullish
April 5, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
AngioDynamics' ( ANGO ) AlphaVac Gets FDA Nod for PE Treatment
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
In Article Trend: Somewhat-Bullish
April 5, 2024 (10:45) / "PR Newswire"
BD Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters - PR Newswire
BD Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters PR ...
In Article Trend: Somewhat-Bullish
April 4, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Why Becton Dickinson ( BDX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Bullish
April 3, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
BDX vs. MMSI: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Becton Dickinson ( BDX Quick QuoteBDX - ) and Merit Medical ( MMSI Quick QuoteMMSI - ) . But which of these two stocks offers value investors a better bang for their buck right now?
In Article Trend: Bullish
April 2, 2024 (14:32) / "Zacks Commentary" (by Zacks Equity Research)
AngioDynamics ( ANGO ) Settles Patent Litigations With BD
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:51) / "Benzinga" (by Nabaparna Bhattacharya)
AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement - Becton Dickinson ( NYSE:BDX ) , AngioDynamics ( NASDAQ:ANGO )
AngioDynamics, Inc. ANGO signed a settlement agreement with Becton, Dickinson And Company BDX to resolve all outstanding patent litigation with C.R. Bard.
In Article Trend: Somewhat-Bullish
March 29, 2024 (16:45) / "Benzinga" (by Benzinga Insights)
Peering Into Becton Dickinson's Recent Short Interest - Becton Dickinson ( NYSE:BDX )
Becton Dickinson's BDX short percent of float has risen 34.72% since its last report. The company recently reported that it has 2.79 million shares sold short, which is 0.97% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
March 28, 2024 (15:17) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain STERIS ( STE ) Stock for Now
Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.
In Article Trend: Somewhat-Bullish
March 28, 2024 (13:50) / "Zacks Commentary" (by Zacks Equity Research)
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
March 26, 2024 (13:31) / "PR Newswire" (by Dickinson and Company))
BD Named Among Fortune's Most Innovative Companies
FRANKLIN LAKES, N.J., March 26, 2024 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) ( NYSE: BDX ) , a leading global medical technology company, today was named to Fortune's 2024 list of America's Most Innovative Companies.
In Article Trend: Bullish
March 26, 2024 (12:54) / "Benzinga" (by Avi Kapoor)
Jim Cramer Says Don't Sell This 'Amazing' Beauty Brand, Believes KKR And Blackstone 'Can Make More Money' - Blackstone ( NYSE:BX ) , Becton Dickinson ( NYSE:BDX )
On CNBC's "Mad Money Lightning Round," Jim Cramer sang the praises of Energy Transfer LP ET, which posted better-than-expected earnings for its fourth quarter. Cramer also mentioned how KKR & Co. Inc. KKR and Blackstone BX are having "a big run now."
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
QIAGEN ( QGEN ) Partners With IPPA to Raise TB Screening Awareness
QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.
In Article Trend: Somewhat-Bullish
March 22, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Point of Care Diagnostics Market is Expected to Reach $77.8 billion | MarketsandMarkets™
Chicago, March 22, 2024 ( GLOBE NEWSWIRE ) -- Point of Care Diagnostics market in terms of revenue was estimated to be worth $49.7 billion in 2023 and is poised to reach $77.8 billion by 2028, growing at a CAGR of 9.4% from 2023 to 2028 according to a latest report published by ...
In Article Trend: Somewhat-Bullish
March 21, 2024 (17:47) / "Benzinga" (by Vandana Singh)
FDA Probe On China-Made Syringes: Becton Dickinson Boosts US Syringe Output Following Concerns - Becton Dickinson ( NYSE:BDX )
Thursday, Becton Dickinson And Co BDX said it increased production of medical syringes in the U.S. after the FDA recommended not using some China-made syringes as part of its ongoing quality probe.
In Article Trend: Neutral
March 19, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Bullish
March 18, 2024 (10:50) / "PR Newswire" (by BD (Becton)
BD and Health Care Consortium in Denmark Find Success in Medical Waste Recycling Study
COPENHAGEN, Denmark, March 18, 2024 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) ( NYSE: BDX ) , a leading global medical technology company, and a consortium of health care institutions in Denmark have innovated a method to recycle used blood collection tubes without compromising ...
In Article Trend: Bullish
March 15, 2024 (14:30) / "PR Newswire" (by Research and Markets)
Prefilled Syringes Market, Industry Trends and Global Forecasts, 2035 - Surge in Dual Chamber Format Adoption Amid Growing Player Base
Prefilled Syringes Market, Industry Trends and Global Forecasts, 2035 - Surge in Dual Chamber Format Adoption Amid ... PR ...
In Article Trend: Neutral
March 15, 2024 (14:15) / "PR Newswire" (by Research and Markets)
$20+ Bn Advanced Wound Care Market Trends and Global Forecasts, 2035
DUBLIN, March 15, 2024 /PRNewswire/ -- The "Advanced Wound Care Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Advanced Wound Care Dressing, Type of Acute Wound Treated, Type of End User, Leading Advanced Wound Care Manufacturers, and Key Geographical Regions" ...
In Article Trend: Somewhat-Bullish
March 14, 2024 (17:00) / "PR Newswire"
Zeus Names New Chief Executive Officer - PR Newswire
Zeus Names New Chief Executive Officer PR ...
In Article Trend: Bullish
March 14, 2024 (17:00) / "Canada Newswire"
Zeus Names New Chief Executive Officer - Canada NewsWire
Zeus Names New Chief Executive Officer Canada ...
In Article Trend: Bullish
March 14, 2024 (15:57) / "Zacks Commentary" (by Zacks Equity Research)
BD's ( BDX ) ADC System Favored by New Study for Long-Term Care
BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.
In Article Trend: Bullish
March 13, 2024 (14:37) / "Benzinga" (by Globe Newswire)
Pharmaceutical Waste Management Market Worth USD 2.4 billion, at a 4.9% CAGR By 2031 - Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 13, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. -The pharmaceutical waste management market was worth US$1.5 billion in 2022. The market is expected to expand at a CAGR of 4.9% from 2023 to 2031 and reach a total of US$ 2.4 billion by ...
In Article Trend: Neutral
March 12, 2024 (14:34) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain BD ( BDX ) to Your Portfolio
BD's (BDX) slew of product launches raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:27) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad ( BIO ) Suffers due to BioPharma Softness, Stiff Competition
Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
In Article Trend: Neutral
March 11, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Autolus Therapeutics announces publication in Blood Cancer Journal - Autolus Therapeutics ( NASDAQ:AUTL )
LONDON, March 11, 2024 ( GLOBE NEWSWIRE ) -- Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled 'Dual T-cell constant β chain ( TRBC ) 1 and TRBC2 ...
In Article Trend: Neutral
March 11, 2024 (09:35) / "Motley Fool" (by Justin Pope)
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
These are some of the best-performing stocks in what's arguably society's most important industry.
In Article Trend: Somewhat-Bullish
March 8, 2024 (22:48) / "PR Newswire"
Protein Expression Market size to grow by USD 2.45 billion from 2023 to 2027, North America accounts for 37% of ... - PR Newswire
Protein Expression Market size to grow by USD 2.45 billion from 2023 to 2027, North America accounts for 37% of ... PR ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (11:42) / "Zacks Commentary" (by Zacks Equity Research)
3 Nationwide Mutual Funds to Enhance Your Portfolio Returns
Consider investing in Nationwide mutual funds like NWAMX, GNWRX and NWHLX for solid returns.
In Article Trend: Somewhat-Bullish
March 7, 2024 (09:59) / "Benzinga" (by Globe Newswire)
Stem Cell Manufacturing Market Worth USD 26.6 billion, Growing At 9.2% CAGR by 2033 - Report By Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 07, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. -The global stem cell manufacturing market is estimated to flourish at a CAGR of 9.2% from 2023 to 2033.
In Article Trend: Bullish
March 7, 2024 (07:31) / "Benzinga" (by Globe Newswire)
Biomarkers Market to Reach USD 125.6 billion by 2031, Projected a CAGR of 10.4%: Report Analysis by Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 07, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global biomarkers market is estimated to flourish at a CAGR of 10.4% from 2023 to 2031.
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:28) / "Zacks Commentary" (by Zacks Equity Research)
BD ( BDX ) Initiates IDE Study to Aid Treatment of Artery Disease
BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:05) / "Benzinga" (by Globe Newswire)
Global Urinary Incontinence Treatment Devices Market Size is Estimated to Reach USD 6.02 billion by 2030, Growing at a CAGR of 6.58%: Straits Research
New York, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- A medical disease called urinary incontinence causes uncontrollable urine loss. Medical devices are used to treat chronic urine incontinence and to grow and strengthen the pelvic floor muscles.
In Article Trend: Neutral
March 4, 2024 (01:12) / "PR Newswire"
Enteral Feeding Devices Market size to grow by USD 1.36 billion from 2022-2027, North America to account for 46% of ... - PR Newswire
Enteral Feeding Devices Market size to grow by USD 1.36 billion from 2022-2027, North America to account for 46% of ... PR ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (19:15) / "PR Newswire" (by Research and Markets)
Multiplex Assays Markets, 2030
DUBLIN, March 1, 2024 /PRNewswire/ -- The "Multiplex Assays Market by Type ( Protein [Bead, Planar], Nucleic Acid, Cell ) Technology ( Flow Cytometry, PCR, Immunoassay ) Application ( R&D, Diagnosis ( Oncology, Cardiovascular, Infectious, Autoimmune Diseases ) Product, End User - Global Forecast ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (13:43) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Omnicell ( OMCL ) Stock Now
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website